Stryker (SYK) Stock Forecast & Price Target

Stryker demonstrated solid performance in its financial metrics, with organic sales growth reaching 11.0% in 4Q25, which reflects a significant increase from the previous quarter's 8.4% growth. Key segments such as knees experienced robust growth of 7.6% in the U.S. and 8.8% internationally, primarily driven by advancements in robotic-assisted procedures. Additionally, the company achieved a notable operating margin of 30.2%, exceeding expectations and indicating strong operational efficiency amidst broad-based strength across its diverse product portfolio.

Stryker’s stock outlook is negatively influenced by several fundamental factors, including anticipated organic revenue growth slowing to 8% or less due to unsatisfactory new product launches and potential revenue dis-synergies stemming from recent acquisitions. The company's gross margin showed a modest decline, down 10 basis points year-over-year to 65.2%, despite improvements in operating margin, indicating challenges in maintaining profitability amidst tariff pressures and competition. Furthermore, risks such as a deceleration in the orthopedic market, reduced hospital capital spending, and difficulties in integrating acquisitions add to the uncertainty surrounding Stryker's future earnings performance.